Cerevance’s most advanced internal program is its Parkinson’s candidate, CVN424. By targeting an indirect pathway associated with the disease, the small molecule is intended to generate the ...

BOSTON, May 09, 2023 (GLOBE NEWSWIRE) -- Cerevance, a private, clinical-stage drug discovery and development company focused on developing novel therapeutics for central nervous system (CNS ...

About Cerevance Cerevance is focused on the development of precision treatments for central nervous system (CNS) disorders, prioritizing chronic neurodegenerative conditions such as Alzheimer's ...

Data from the Phase 1 clinical trial of novel KCNK13 inhibitor showed good CNS exposure and was generally well-toleratedProprietary NETSseq platform explores the key potential role of astrocytes in Al ...

BOSTON--(BUSINESS WIRE)-- Cerevance, a clinical stage biopharmaceutical company advancing new medicines for brain diseases, today announced the appointment of Aoife Brennan, M.B., B.Ch., to its ...

Cerevance came to life in 2016 with $36 million in series A funding and a 25-person neuroscience research team from its site in Cambridge, U.K. Takeda and the VC firm Lightstone contributed $21.5 ...

BOSTON, MA, April 14, 2020 (GLOBE NEWSWIRE) -- Cerevance, a private drug discovery and development company focused on brain diseases, has closed a Series B financing, bringing in $45 million from ...

The Dementia Discovery Fund, which is managed by SV Life Sciences, has invested $5 million in the initial financing round of Cerevance. Cerevance, a drug discovery company with offices in Boston ...

BOSTON--(BUSINESS WIRE)--Cerevance, a clinical stage biopharmaceutical company advancing new medicines for brain diseases, has successfully completed its Phase 1 clinical trial of CVN424, the ...

Cerevance, based in Boston, set out in January to raise $60 million. By late March, however, the company had elected to lock in the first $45 million, due to the upheaval caused by the coronavirus ...

Cerevance is focused on advancing cell type-specific therapies for the treatment of neurodegenerative and central nervous system-controlled metabolic disorders.

BOSTON--(BUSINESS WIRE)--Cerevance, a clinical stage biopharmaceutical company advancing new medicines for brain diseases, today announced the appointment of Aoife Brennan, M.B., B.Ch., to its ...